Biotech Cytomos has announced a trio of appointments to its leadership team, to grow its cell analysis tech ahead of its Series A funding round.
David Rigterink has been appointed as CEO and to the board. Dr Lindsay Fraser joins the Cytomos leadership team as chief scientific officer (CSO) and Gordon Sharp has been promoted to interim chief technology officer (CTO).
The new appointments will focus on product development, moving to a new HQ and securing Series A investment.
It comes after the Edinburgh-based company added £1.6m of capital to its seed round in July for its cell analysis platform, Cytomos Dielectric Spectroscopy (CDS).
“With our new executive team and funding in place, Cytomos is well positioned to accelerate its pace of growth and advance the development of our novel process analytical technology platform,” said Dr Alan Raymond, chairman, Cytomos.
Cytomos’ cell platform has potential applications in drug development, bioprocessing, cell and gene therapy manufacturing and vaccine production.
David Rigterink, CEO, Cytomos said: “Through the development of our CDS technology platform, Cytomos has a powerful tool which will help the scientific community to bring novel therapies to market faster and radically reduce costs by making game-changing decisions earlier.”
Rigterink previously worked for biopharma startup Single Use Support and has held positions at Sartorius Stedim Biotech.
Dr Fraser has experience at Symbiosis Pharmaceutical Service, SNBTS, Milteny Biotech, and Roslin CT.
Cytomos’ seed round was led by Archangels, which in a recent report revealed they had added £1.4bn to the Scottish economy.